Galectin Therapeutics
GALT
GALT
65 hedge funds and large institutions have $37.3M invested in Galectin Therapeutics in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
25% less call options, than puts
Call options by funds: $2.04M | Put options by funds: $2.71M
Holders
65
Holding in Top 10
–
Calls
$2.04M
Puts
$2.71M
Top Buyers
| 1 | +$1.86M | |
| 2 | +$1.44M | |
| 3 | +$1.03M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$964K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$903K |
Top Sellers
| 1 | -$1.07M | |
| 2 | -$223K | |
| 3 | -$216K | |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$145K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$80K |